Holen Sie sich die Stockscreener-App
59.33
0.45%
-0.27
Handel nachbörslich:
59.00
-0.33
-0.56%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt BMY?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Bristol Myers Squibb Co Aktie (BMY) Neueste Nachrichten
Trump Imposes 100% Drug Tariffs: 5 Pharma Stocks That Won’t Pay a Dime - Investing.com
Scotiabank Maintains Bristol-Myers Squibb(BMY.US) With Hold Rating, Maintains Target Price $60 - 富途牛牛
Pleural Diseases Market Set to Boom Rapidly by 2033 |Bristol Myers Squibb, Merck & Co., Inc., GlaxoSmithKline plc - openPR.com
Nathan Pennell: "Global and Local" Model Takes Focus During BMS Japan Visit - Oncodaily
Case-By-Case Guide As Justices Eye Landmark Pharma Law - Law360
Bristol-Myers Squibb Company (BMY) stock price, news, quote and history - Yahoo Finance Singapore
Trust Co. of Toledo NA OH Sells 55,523 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb Company (BMY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Bristol-Myers Squibb Company (BRM.F) Stock Price, News, Quote & History - Yahoo! Finance Canada
Bristol-Myers Squibb Company (BMY) latest stock news and headlines - Yahoo Finance Australia
Elkins, Bristol Myers Squibb CFO, sells $1.85 million in BMY stock - Investing.com Australia
Bristol-Myers Squibb Cancer Moves And Equity Efforts Underpin Valuation Case - Yahoo Finance UK
Growth and Income Portfolio's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol-Myers Squibb Company (BMY) Options Chain - Yahoo! Finance Canada
Elkins, Bristol Myers Squibb CFO, sells $1.85 million in BMY stock By Investing.com - Investing.com South Africa
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors - marketwatch.com
Bristol-Myers Squibb Co (BMY) Shares Down 3.58% on Apr 2 - GuruFocus
Bristol Myers Squibb and Gilead Sciences are putting their media accounts into review - Ad Age
Bristol Myers Squibb Cancer Pact And Equity Push Raise Valuation Questions - simplywall.st
Bristol-Myers Squibb Co Stock (BMY) Moved Down by 3.58% on Apr 2: What Signal Does It Send? - TradingKey
Bristol-Myers Squibb (BMY) Announces Positive Data from the Phase 3 SCOUT-HCM Trial of Camzyos - Insider Monkey
Ritter Alpha, LP's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Tema Etfs LLC Has $6.89 Million Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
20,914 Shares in Bristol Myers Squibb Company $BMY Acquired by J. Safra Sarasin Holding AG - MarketBeat
F&V Capital Management LLC Boosts Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Allspring Global Investments Holdings LLC Buys 67,783 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
DF Tactical Dividend Fund's Bristol-Myers Squibb Co(BMY) Holding History - gurufocus.com
Janux announces development candidate nomination under Bristol Myers collab - tipranks.com
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - marketwatch.com
Bristol Myers Squibb Target of Unusually High Options Trading (NYSE:BMY) - MarketBeat
Piramal Pharma Completes Acquisition of Kenalog Injectable Product from Bristol-Myers Squibb - scanx.trade
Bristol Myers Squibb (BMY) Partners with Janux on New Cancer The - GuruFocus
Janux Unveils Development Candidate in Bristol Myers Squibb Partnership, Worth $35M Milestone - Contract Pharma
Janux Therapeutics receives $35M milestone from Bristol Myers Squibb - Investing.com
Janux Therapeutics receives $35M milestone from Bristol Myers Squibb By Investing.com - Investing.com India
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment - Yahoo Finance Singapore
Bristol Myers Squibb Company $BMY Shares Sold by Meyer Handelman Co. - MarketBeat
Advanced Renal Cell Carcinoma Treatment Market to Grow by $3.1 Billion During 2026-2030: Global Industry Assessment Featuring Pfizer, Merck & Co., Bristol-Myers Squibb, AstraZeneca, Novartis and More - finance.yahoo.com
Bristol Myers Squibb Co. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Bristol Myers Squibb Discounts Sotyktu, Zeposia, Orencia SC on Government SiteNews and Statistics - IndexBox
Bristol Myers Squibb Co. stock rises Tuesday, still underperforms market - marketwatch.com
Bristol Myers Squibb Stock: Dividend Reliability and Pipeline Momentum Define Investor Appeal in 202 - AD HOC NEWS
Is Bristol Myers Squibb (BMY) Price Near US$60 Supported By Cash Flow And Earnings Models - simplywall.st
Kidney Cancer Drugs Market to Grow by $2 Billion During - globenewswire.com
Kidney Cancer Drugs Market to Grow by $2 Billion During 2026-2030: Pfizer, Novartis, Exelixis, Roche, Bristol Myers Squibb Company, and Bayer Lead the Industry - Yahoo Finance
Ovarian Cancer Drugs Market Outlook Report 2026-2030 - GlobeNewswire
Ovarian Cancer Drugs Market Outlook Report 2026-2030 Featuring Strategic Analysis of AstraZeneca, Roche, Bristol-Myers Squibb Company, Clovis Oncology, Pfizer and Other Key Players - Yahoo Finance
Bristol Myers Squibb launches survey on myeloma care gaps By Investing.com - Investing.com India
Mn Services Vermogensbeheer B.V. Increases Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Retirement Systems of Alabama Boosts Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb adding 3 medications on TrumpRx - Fox Business
Multiple Myeloma Market Is Going to Boom Rapidly | Bristol-Myers - openPR.com
Should You Buy Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming Dividend? - simplywall.st
Pancreatic Adenocarcinoma Treatment Market to Grow at 13% CAGR During 2026-2030, Led by Pfizer, Roche, Merck & Co., Sanofi, Bristol-Myers Squibb, AstraZeneca, Novartis, and GlaxoSmithKline - Yahoo Finance
Bristol-Myers Squibb Gets FDA Approval for Hodgkin’s Lymphoma Treatment - Insider Monkey
Jim Cramer on Bristol-Myers Squibb: “The stock’s recent pullbacks have represented terrific buying opportunities” - MSN
Is Bristol-Myers Squibb Company (BMY) A Good Stock To Buy Now? - Insider Monkey
Bristol Myers Squibb Stock: Strong Growth Portfolio and Dividend Yield Position BMY Shares as a Valu - AD HOC NEWS
Bristol Myers Squibb’s Camzyos shows promise in adolescent trial By Investing.com - Investing.com UK
Bristol Myers Squibb’s Camzyos shows promise in adolescent trial - Investing.com
Heart drug cuts blockage in teens with rare heart disease, trial shows - Stock Titan
A Look At Bristol Myers Squibb (BMY) Valuation As Growth Portfolio Outperforms Recent GAAP Loss - simplywall.st
1.73%
0.30%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):